CD44v8-10 mRNA contained in serum exosomes as a diagnostic marker for docetaxel resistance in prostate cancer patients
Open Access
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- CD44 Splice Variant v8-10 as a Marker of Serous Ovarian Cancer PrognosisPLOS ONE, 2016
- CD82 suppresses CD44 alternative splicing-dependent melanoma metastasis by mediating U2AF2 ubiquitination and degradationOncogene, 2016
- Serum exosomal P-glycoprotein is a potential marker to diagnose docetaxel resistance and select a taxoid for patients with prostate cancerUrologic Oncology: Seminars and Original Investigations, 2015
- Up-regulation of CD44 in the development of metastasis, recurrence and drug resistance of ovarian cancerOncotarget, 2015
- CD44v8-10 Is a Cancer-Specific Marker for Gastric Cancer Stem CellsCancer Research, 2014
- Nanoways to overcome docetaxel resistance in prostate cancerDrug Resistance Updates, 2014
- Exosomal miRNAs as Biomarkers for Prostate CancerFrontiers in Genetics, 2013
- Exosomes as Biomarker Treasure Chests for Prostate CancerEuropean Urology, 2011
- Hyaluronan-CD44 Interaction Activates Stem Cell Marker Nanog, Stat-3-mediated MDR1 Gene Expression, and Ankyrin-regulated Multidrug Efflux in Breast and Ovarian Tumor CellsJournal of Biological Chemistry, 2008
- Molecules in focus The CD44 protein familyThe International Journal of Biochemistry & Cell Biology, 1998